NCT06430866: An ongoing trial by Amgen
This trial is ongoing. It must report results 1 year, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06430866 |
|---|---|
| Title | A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pembrolizumab) in Participants With Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 12, 2024 |
| Completion date | Dec. 14, 2026 |
| Required reporting date | Dec. 14, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |